Anthera Pharmaceuticals Inc.
Description Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing products to treat diseases associated with inflammation and autoimmune diseases. The companys primary product candidate is blisibimod, which is in Phase III clinical trials targeting elevated levels of B-cell activating factor (BAFF) associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others. It has a license agreement with Amgen Inc. to develop and commercialize BAFF inhibitor blisibimod, as well as non-exclusive rights to certain technology relating to peptibody compositions and formulations. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California. To view the detailed information, you need to SUBSCRIBE with us. |
 |